A Controlled, Parallel Group, Open-label, Multicenter Extension Study to Investigate Efficacy and Safety of Oral BAY85-3934 and Active Comparator (Epoetin Alfa / Beta) in the Long-term Treatment of Subjects With Anemia Associated With Chronic Kidney Disease Who Are on Dialysis in the United States and Japan.

Trial Profile

A Controlled, Parallel Group, Open-label, Multicenter Extension Study to Investigate Efficacy and Safety of Oral BAY85-3934 and Active Comparator (Epoetin Alfa / Beta) in the Long-term Treatment of Subjects With Anemia Associated With Chronic Kidney Disease Who Are on Dialysis in the United States and Japan.

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Mar 2017

At a glance

  • Drugs Molidustat (Primary) ; Epoetin alfa; Epoetin alfa; Epoetin beta; Epoetin beta
  • Indications Anaemia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms DIALOGUE5
  • Sponsors Bayer
  • Most Recent Events

    • 10 Jan 2017 Status changed from active, no longer recruiting to completed.
    • 02 Nov 2016 Planned End Date changed from 1 Oct 2018 to 1 Dec 2016.
    • 02 Nov 2016 Planned primary completion date changed from 1 Oct 2018 to 1 Nov 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top